Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)

Acute myeloid leukemia (AML) with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) is a specific and aggressive subtype of blood cancer. In this disease, the bone marrow — the spongy tissue inside your bones that makes blood cells — starts producing abnormal white blood cells that do not work properly. These abnormal cells crowd out healthy blood cells, leading to problems like infections, anemia (low red blood cells), and easy bleeding or bruising. What makes this subtype unique is a specific change in chromosome 3, where a piece of the chromosome either flips around (called an inversion) or swaps places between two copies of chromosome 3 (called a translocation). This rearrangement causes a gene called MECOM (also known as EVI1) to become overactive, which drives the cancer. This subtype is also commonly associated with abnormal platelet counts (the cells that help blood clot), which can sometimes be normal or even elevated, unlike most other forms of AML where platelet counts are low. This form of AML is considered high-risk because it tends to respond poorly to standard chemotherapy. It is classified by the World Health Organization as a distinct entity because of its unique biology and challenging prognosis. Treatment typically involves intensive chemotherapy followed by a stem cell transplant (also called a bone marrow transplant) when possible, as this offers the best chance for long-term remission. Unfortunately, even with aggressive treatment, this subtype has a higher rate of relapse compared to many other forms of AML. Clinical trials exploring new targeted therapies are an important option for patients with this diagnosis.

Bring these to your next appointment

• Q1.What is the exact genetic profile of my leukemia, and how does it affect my treatment options?,Am I a candidate for a stem cell transplant, and if so, when would that happen?,Are there any clinical trials available for this specific type of AML that I should consider?,What are the expected side effects of the recommended treatment, and how will they be managed?,What is my realistic prognosis, and what factors could improve or worsen my outcome?,How often will I need blood tests and bone marrow biopsies to monitor my response to treatment?,What support services are available to help me and my family cope with this diagnosis?

Common questions about Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)

Related conditions

Other rare diseases commonly researched alongside Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).

• Acute myeloid leukemia with t(6;9)(p23;q34)→